Pharma News, 2024

Orchid Pharma has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market its new chemical entity (NCE), the active pharmaceutical ingredient (...

Founded in 2012, Cycle focuses on developing drug treatments and related services for rare diseases.  

There are currently only two FDA-approved treatments for the chronic lung disease.

Repare Therapeutics’ RPTX shares jumped 13.9% on Jun 5 after the FDA granted the Fast Track designation to its investigational combination therapy of lunresertib and camonsertib to treat adult p...

The US Food and Drug Administration (FDA) has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101 for the treatment of haemophilia B.

Key trends in the global small molecule injectable drugs market up to 2033 include advancements in technology, drug delivery systems and fast-track approvals of new drug formulations, research predict...

A panel of experts advising the Food and Drug Administration on the use of the psychedelic MDMA for post-traumatic stress disorder found on Tuesday that the available evidence fails to show that the d...

Bluejay Therapeutics has released positive preliminary data from a Phase II study of its human IgG1 monoclonal antibody, BJT-778, for the treatment of patients with chronic hepatitis D (CHD).

The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left four major drugmakers—GSK, Pfizer, Sanofi and Boehringer Ingelheim—vulner...

Aurigene Pharmaceutical Services, a Dr Reddy’s Laboratories unit, has officially opened a new biologics facility at Genome Valley in the Indian city of Hyderabad.

California-based biotech Quince Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for its ataxia-telangiectasia (A-T) drug EryDex.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has backed approval for Akantior (polihexanide), a potential first medicine to tre...